Ande, Sudharsana Rao ; Chen, Junjie ; Maddika, Subbareddy (2009) The ubiquitin pathway: An emerging drug target in cancer therapy European Journal of Pharmacology, 625 (1-3). pp. 199-205. ISSN 0014-2999
Full text not available from this repository.
Official URL: http://doi.org/10.1016/j.ejphar.2009.08.042
Related URL: http://dx.doi.org/10.1016/j.ejphar.2009.08.042
Abstract
Ubiquitination is a highly ordered multistep enzymatic process, carried out by a well-defined systematic ubiquitin pathway, which is required for maintaining appropriate levels and functional activities of various cellular proteins. Targeted regulation of proteins by ubiquitin pathway controls numerous cellular processes including cell proliferation, signal transduction, apoptosis, transcriptional regulation, receptor modulation as well as endocytosis. Significant progress has been made in recent years in not only understanding the structure, function and important regulatory roles of ubiquitin network but also the alterations of ubiquitin pathway in various human diseases including cancer. Based on the progress made, it is now possible to target specifically various components involved in the ubiquitin pathway such as E3 ubiquitin ligases, deubiquitinases and proteosome for potential anticancer therapies. Here we review the potential drug targets available in the ubiquitin system and the small molecule inhibitors that can target these components in the pathway, which can be developed into novel anticancer therapeutics in the near future.
Item Type: | Article |
---|---|
Source: | Copyright of this article belongs to Elsevier Science. |
Keywords: | Ubiquitin E3; Ligase; Proteosome; Deubiquitinases; Inhibitors; Cancer Therapy. |
ID Code: | 118579 |
Deposited On: | 25 May 2021 13:06 |
Last Modified: | 25 May 2021 13:06 |
Repository Staff Only: item control page